CYSTO-CONRAY II SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

IOTHALAMATE MEGLUMINE

Dostupno od:

LIEBEL-FLARSHEIM COMPANY LLC

ATC koda:

V08AA04

INN (International ime):

IOTALAMIC ACID

Doziranje:

172MG

Farmaceutski oblik:

SOLUTION

Sastav:

IOTHALAMATE MEGLUMINE 172MG

Administracija rute:

URETHRAL

Jedinice u paketu:

250/500ML

Tip recepta:

Ethical

Područje terapije:

ROENTGENOGRAPHY

Proizvod sažetak:

Active ingredient group (AIG) number: 0102763004; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2021-12-02

Svojstava lijeka

_ _
_Page 1 of 14_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CYSTO-CONRAY
® II
Iothalamate Meglumine Injection USP
17.2 % w/v
Solution
IONIC IODINATED RADIOGRAPHIC CONTRAST MEDIUM FOR INSTILLATION OF THE
URINARY TRACT.
Liebel-Flarsheim Company LLC Date of Revision:
8800 Durant Road November 26, 2021
Raleigh, North Carolina
27616 USA
Importer:
Liebel-Flarsheim Canada Inc.
7500 Trans-Canada Highway
Pointe-Claire, Quebec
H9R 5H8
Submission Control No.: 255550
_ _
_ _
_Page 2 of 14_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................5
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
DETAILED PHARMACOLOGY
.....................................................................................10
REFER